ACELYRIN shares surge on buyout interest

Published 21/02/2025, 13:26
© Reuters.

Investing.com -- Shares of ACELYRIN, INC. (Nasdaq: SLRN) soared 16% following the company’s confirmation of an unsolicited buyout proposal from Concentra Biosciences. The late-stage clinical biopharma firm, specializing in immunology treatments, is currently poised for a merger with Alumis Inc. (Nasdaq: ALMS), anticipated to finalize in the second quarter of 2025.

The interest from Concentra Biosciences includes an offer to purchase all outstanding shares of ACELYRIN at $3.00 each, plus a contingent value right tied to 80% of net proceeds from potential future licensing or sale of the company’s development programs or intellectual property. This proposal comes as ACELYRIN is navigating through a previously announced merger agreement with Alumis, which remains subject to stockholder approval and other customary closing conditions.

ACELYRIN’s board has expressed its dedication to fulfilling its fiduciary duties, acting in the best interests of all shareholders, and adhering to the terms of its current merger agreement with Alumis. The company has advised its shareholders that no immediate action is required on their part in response to the buyout interest.

Financial advisory for ACELYRIN is being provided by Guggenheim Securities, LLC, with Fenwick & West LLP and Paul Hastings LLP serving as legal counsel. The unsolicited indication of interest from Concentra Biosciences has introduced a new dynamic to ACELYRIN’s future, potentially reshaping the company’s trajectory ahead of the planned merger with Alumis.

As the situation develops, ACELYRIN has pledged to keep shareholders informed of any significant updates. The market’s reaction to the news of potential acquisition interest reflects investor anticipation of the strategic decisions that will shape the company’s path forward.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.